NervGen Restates Q2 Results to CAD 10.8 Million Net Income From Net Loss

NervGen Pharma restated financial statements to correct material stock-option and warrant-derivative valuation errors, as well as misclassified share issuance costs. Net income for the six months ended June 30, 2026, was corrected to CAD 8.88 million from a CAD 30.89 million loss. Warrant derivative liabilities at June 30, 2026, fell to CAD 39.06 million from CAD 68.63 million. Shareholders' equity increased to CAD 46.84 million from CAD 17.28 million. The errors affected periods beginning in fiscal 2020 through June 30, 2026; corrections did not affect cash flows or cash runway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-116634), on October 16, 2026, and is solely responsible for the in